Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Non-Current Assets (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Other Non-Current Assets data on record, last reported at $18.3 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 11.6% year-over-year to $18.3 million; the TTM value through Dec 2025 reached $18.3 million, down 11.6%, while the annual FY2025 figure was $18.3 million, 11.6% down from the prior year.
  • Other Non-Current Assets reached $18.3 million in Q4 2025 per PTCT's latest filing, down from $19.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $75.2 million in Q1 2021 and bottomed at $18.3 million in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $39.7 million, with a median of $35.9 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: surged 133.56% in 2021, then tumbled 48.73% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $46.5 million in 2021, then grew by 4.48% to $48.6 million in 2022, then fell by 25.39% to $36.2 million in 2023, then tumbled by 42.88% to $20.7 million in 2024, then dropped by 11.6% to $18.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $18.3 million in Q4 2025, $19.4 million in Q3 2025, and $21.8 million in Q2 2025.